Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Colorectal Neoplasms 206Colonic Neoplasms 89Rectal Neoplasms 88Stomach Neoplasms 57Pancreatic Neoplasms 49Neoplasms 42Esophageal Neoplasms 42Neoplasm Metastasis 39Unspecified Adult Solid Tumor, Protocol Specific 30Lung Neoplasms 28Glioblastoma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Central Nervous System Neoplasms 23Glioma 22Small Cell Lung Carcinoma 21Neuroblastoma 20Astrocytoma 18Adenocarcinoma Of Esophagus 18Esophageal Squamous Cell Carcinoma 17Gliosarcoma 16Breast Neoplasms 15Rhabdomyosarcoma 13Oligodendroglioma 12Sarcoma 11Adenocarcinoma 10Medulloblastoma 9Carcinoma, Hepatocellular 9Sarcoma, Ewing 8Gastrointestinal Neoplasms 8

Interventions

Irinotecan 2vistusertib 1sapanisertib 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1ZD4054 1Topotecan 1HM781-36B 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Solid Malignancies × Irinotecan × Clear all
NCT00986843 2013-04-05

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
14 enrolled

Advanced Solid Malignancies

NCT00979563 2011-12-07

Oratecan-101

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
15 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡